CD274 and pneumonitis: Our meta-analysis demonstrated that PD-1/ PD-L1 inhibitors including nivolumab, pembrolizumab, and Atezolizumab could increase the risk of all-grade pneumonitis, which was not seen in CTLA4 inhibitor (ipilimumab).